NMS-03305293 + topotecan

NMS-03305293 + topotecan is an investigational combination therapy under clinical evaluation for the treatment of recurrent ovarian cancer. NMS-03305293 is an orally available, selective **PARP-1 inhibitor** (poly ADP-ribose polymerase 1 inhibitor) with a non-trapping profile and brain-penetrant properties, designed to enhance tolerability when combined with chemotherapy agents like topotecan. Topotecan is an approved **topoisomerase I inhibitor** administered intravenously and is widely used as chemotherapy for various cancers, including ovarian and small cell lung cancer. The combination aims to achieve synergistic anti-tumor activity by targeting distinct but complementary DNA repair and damage pathways. Nerviano Medical Sciences developed NMS-03305293, and topotecan is manufactured by multiple companies and is widely available as a generic injectable chemotherapeutic.

Other names

NMS-293 + topotecan